High-dose chemotherapy and autologous stem cell transplantation are used increasingly to treat patients with light-chain-related amyloidosis (AL). Treatment-related mortality is approximately 15%. To enable more patients to undergo stem cell transplantation, a risk-adapted strategy has been developed to treat with lower chemotherapy doses those patients who are at excessive risk. It is unclear whether reducing the chemotherapy dose in patients at excessive risk of treatment toxicity reduces the overall response. We retrospectively reviewed 171 AL patients who underwent conditioning chemotherapy with stem cell transplantation. The patients comprised two groups: those receiving standard high-dose melphalan and those receiving intermediate-dose melphalan. Responses were categorized as hematologic response, which used criteria for myeloma response. The two groups showed statistically significant differences; the overall response rates were 75% in the high-dose group and 53% in the intermediate-dose group although treatment-related mortality was the same in both groups. Reducing the melphalan dose appeared to render more AL patients eligible for stem cell transplantation but sacrificed an element of response. Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy.
1
The median survival ranges from 12 to 17 months. 2 Highdose chemotherapy and autologous stem cell transplantation for AL patients have a higher response rate than conventional chemotherapy alone. 3 This treatment group, however, is highly selected for patients who are clinically able to receive intensive chemotherapy; these patients are not directly comparable to an unselected cohort of AL patients. 4 Certain subsets of AL patients have unacceptably high morbidity and mortality associated with high-dose chemotherapy and stem cell transplantation, and a riskadapted approach has been proposed to allow otherwise ineligible patients to receive an attenuated form of conditioning chemotherapy with anticipated lower risk. 5, 6 Whether modification of the conditioning dose provides comparable response rates is unclear, however. The purpose of this study was to review our outcomes in patients receiving conditioning chemotherapy at various intensities before undergoing stem cell transplantation.
Patients and methods
The AL diagnosis was confirmed with Congo red-stained tissue biopsy specimens in all patients. 7 Patients whose disease was limited to cutaneous involvement, purpura, or carpal tunnel syndrome were excluded. The diagnosis of light-chain-related AL required evidence of a serum or urine monoclonal light chain or the presence of clonal plasma cells in the bone marrow. To determine the type of amyloid, amyloid deposits were stained immunohistochemically with amyloid P component (as a positive control), k and l immunoglobulin light chains, and transthyretin. 8 The baseline evaluation of all patients being considered for stem cell transplantation included echocardiography.
To assess patients for a risk-adapted approach, the number of organs involved was counted. Vascular only amyloid deposits seen on upper endoscopic and rectal biopsy specimens were not considered as organ involvement. The five categories of organ involvement were heart, kidney, liver, nerve, and soft tissue, the last of which included arthropathy, tongue enlargement, and other nonvisceral manifestations of AL. Renal involvement was defined as either kidney biopsy proof of amyloid deposition or a 24-h urinary protein loss of more than 1000 mg/day, predominantly albumin. Hepatic involvement required either liver biopsy proof of amyloid deposition or a splenectomy specimen obtained at the time of splenic rupture, or a liver 5 cm or more below the right costal margin that could not be enlarged because of right-sided heart failure. In addition, the serum alkaline phosphatase level had to exceed the institutional normal. Cardiac involvement required a positive endomyocardial biopsy or unequivocal echocardiographic evidence of AL. Orthostatic hypotension and arrhythmias were not considered as criteria for cardiac AL. Peripheral neuropathy required classic and symptomatic sensorimotor peripheral neuropathy documented by electromyography. Electromyographic evidence without symptoms was not considered a syndrome. Soft tissue AL was defined on the basis of clinical criteria alone. The Mayo Foundation Institutional Review Board approved this retrospective review, and patients studied had provided written informed consent in accordance with Minnesota law.
The conditioning regimen was determined by consensus among three of the investigators (MAG, MQL, AD). A point system was devised to allocate patients to conditioning on a risk-adjusted basis. The criteria used to determine the dose included the number of organs involved (soft tissue involvement was not considered in counting organs for risk-adjusted dosing), the ejection fraction, age, New York Heart Association class, alkaline phosphatase value, and serum creatinine value. Patients with one or two organs involved, an ejection fraction 450%, age o65 years, New York Heart Association class I or II, alkaline phosphatase o4 times the institutional normal, and serum creatinine o176 mmol/l were all assigned 0 points. Patients received 1 point each if any of the following were present: 42 organs involved, age 465 years, or alkaline phosphatase 44 times the institutional upper limit of normal. Patients were assigned 2 points each if their ejection fraction echocardiographically was o50%, serum creatinine was X176 mmol/l, or New York Heart Association class was III (patients in New York Heart Association class IV were not eligible for transplant). Patients with 0-2 points were considered low risk and received high-dose conditioning. Patients with 3 points were considered intermediate risk and The hematologic response criteria conformed to those established for multiple myeloma. 10 All patients who had measurable serum or urine M protein were monitored for changes in the M peak. A response required a 50% reduction in the size of the serum or urine M peak after transplantation. Two response criteria were applied when the light-chain or the immunoglobulin protein was detectable but not quantifiable by electrophoresis. The first required complete eradication of the immunoglobulin light chain as seen by immunofixation and o5% marrow plasma cells. Beginning in June 2002, the immunoglobulin free light-chain assay was applied to quantify the free light chains. When this second criterion was applied, the free light-chain value had to diminish by more than 50% as long as the pretransplant level was greater than 0.10 g/l (normal less than 0.03 g/l). 11, 12 Light-chain response was assessed on day þ 100.
For the patient to be considered for transplantation, a minimum of 2 Â 10 6 CD34 cells/kg was required. However, our target was 5 Â 10 6 CD34 cells/kg, and apheresis was typically continued in an attempt to achieve this level. 13 Apheresis was performed by processing 11-14 l of blood in 4 h. Mobilization was by cyclophosphamide 3 g/m 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) in 36 and by G-CSF alone in 135.
Supportive care was standard for prospective transplant patients, including prophylactic fluoroquinolone antibiotics and fluconazole. Patients were treated as outpatients and were hospitalized for persistent neutropenic fever or intractable mucositis or dehydration. Total body irradiation of 2 Gy was given twice daily on days À4, À3, and À2 and melphalan on day À1. All others received half the melphalan dose on days À2 and À1.
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Statistical analysis
The main end point of the study was the presence or absence of hematologic response. Survival was analyzed by the Kaplan-Meier method.
14 Laboratory data obtained at baseline were compared between the groups by using w 2 tests for categorical data and two-sample t-tests and ranksum tests for continuous variables. All statistical tests were two sided, and the threshold for significance was 0.05. All analyses were performed with the use of StatView. 
Results
Patient cohort
Between March 8, 1996 , and November 25, 2003, a total of 171 patients underwent autologous stem cell transplantation. The characteristics of these patients are given in Table 1 . All except 12 patients had evidence of an M protein in the serum or urine (Table 2 ). k and l amyloid represented 24 and 76%, respectively. At the time of diagnosis, AL signs or symptoms were seen in the kidney in 115 (67%), the heart in 84 (49%), the peripheral nerves in 25 (15%), and the liver in 31 (18%). The histologic diagnosis of AL was established by a rectal biopsy in 14 of 17 patients, a positive renal biopsy in 84, a positive cardiac biopsy in 30, and a positive hepatic biopsy in 11 of 12. Deposits of amyloid in fat were found in 111 of 153 patients (73%) and in the bone marrow in 125 of 166 patients (75%). 
Conditioning
Patients were separated into two groups on the basis of conditioning regimen. , plus total body irradiation, 12 Gy. All patients had stem cells infused on day 0. Any patient who died as a result of therapy was considered a treatment failure, including one mobilization death, for the purpose of analysis (intent to treat). The response rates are given in Table 3 . The observed response frequency for patients in the high-dose conditioning group was significantly higher than that in the intermediate-dose group (75 vs 53%; Po0.01).
An attempt to look at more homogeneous subgroups of patients for differences in response based on regimen intensity was also attempted. When the analysis was limited to those 76 patients whose urinary protein was less than 3 g/ day (non-nephrotic amyloid), there were 51 patients who received high-dose therapy, of whom 40 responded (78%). There were 25 in the intermediate-dose group and 12 responded (48%) (Po0.01). In evaluating patients with cardiac amyloid, the 73 patients whose ejection fraction was less than 65% were analyzed: 44 of these patients received high-dose therapy and 36 responded (82%); 29 patients received intermediate-dose therapy and 14 responded (48%) (Po0.01). When patients whose septal thickness was greater than 12 mm were analyzed (n ¼ 83), 50 received high-dose therapy and 36 (72%) responded, and 33 received intermediate-dose therapy and 15 responded (45%) (Po0.02). The finding of significant differences in response, based on regimen intensity, in relatively homogeneous subgroups of patients suggests that the superiority of the higher-dose melphalan is not simply a function of patient selection.
The presence of a response had a profound impact on outcome. When all 171 patients were analyzed, there were 117 responders (12 of whom have died to date) and 51 nonresponders (31 of whom have died to date). The median survival of nonresponders is 12.6 months. The median survival of the responders has not yet been reached. The projections demonstrate that the median survival will exceed 6 years, but these are guarded because 90% of the values are censored. However, the difference in survival is significant (Po0.0001). When the patients receiving highdose therapy were analyzed individually for response, there were 120 patients receiving high-dose treatment: 90 responders and 30 nonresponders. Of the 90 responders, seven have died, and of the 30 nonresponders, 14 have died. The projected median survival of the nonresponders in the high-dose group is 34 months, but this has not been reached for the responders (Po0.001). In the 51 patients who received intermediate-dose therapy, there were 27 responders and 24 nonresponders. Of the 27 responders, only five have died. Of the 24 nonresponders, 17 have died, with a median survival of 9.1 months. Differences between responders and nonresponders were significant (Po0.0001). Response is an important predictor of overall survival. There was no survival difference among responders based on whether they received high-or intermediatedose chemotherapy. Similarly, no survival difference was seen in nonresponders based on conditioning intensity (P40.1). However, the proportion of responders is higher in the high-dose group. This same conclusion was reached previously in patients receiving traditional-dose therapy. 15 In univariate analysis, the b 2 -microglobulin value, creatinine value, serum M-protein spike level, and number of organs involved before transplantation were associated with mortality. In a Cox multivariate analysis, only the number of AL-involved organs before transplantation and the serum creatinine level before transplantation were associated with treatment-related mortality. The hazard ratio was 0.20 (range 0.10-0.45) for involvement of one organ (P ¼ 0.001) and 2.0 (range 1.2-3.4) for creatinine value (P ¼ 0.006) as a continuous variable. Median survival has not been reached by patients with one or two involved organs and was 21.5 months for patients with more than two involved organs at the time of transplantation. Of the 171 patients, 11 died before post transplant day 30. Treatment-related mortality for the entire group was 12% and was defined as any death occurring before post transplant day 100 without regard to cause. Nine of the patients died of sudden cardiac deaths related to their cardiac amyloid. Two died of massive hepatic failure with pre-existent advanced hepatic amyloid. Three developed postchemotherapy renal insufficiency and died of dialysisrelated complications. There was one brain-stem hemorrhage during the period of thrombocytopenia. Three patients died of pneumonia during neutropenia, and three died of multiorgan failure postconditioning; all had more than two organs involved. Of the 21 treatment-related deaths, the serum creatinine value ranged from 79 to 343 with a median of 114 mmol/l. Four of the 21 patients had a pretransplant creatinine X176 mmol/l, 14 had cardiac involvement, and seven had three or more organs involved. The response rate was independent of the number of organs involved. For one, two, and more than two organs, the response rates were 61 of 80, 40 of 62, and 16 of 29, respectively (P40.08).
The two groups of patients were not comparable because of the process used to select each patient's treatment. There were no differences between the intermediate-and high- dose groups in terms of sex, age, levels of serum albumin, C-reactive protein, and bone marrow plasma cells. As might be expected, significant differences were evident between the groups in serum creatinine value (106 vs 97 mmol/l (P ¼ 0.001)), serum b 2 -microglobulin value (219 vs 181 nmol/l (P ¼ 0.001)), echocardiographic interventricular septal thickness (14.0 vs 12.0 mm (P ¼ 0.002)), and echocardiographically measured ejection fraction (62 vs 66% (P ¼ 0.01)) ( Table 1 ). The number of organs involved was greater in the intermediate-dose group; 69% had more than one organ involved compared with 47% in the highdose group (P ¼ 0.01). Although survival was not an end point of this study, at the time of last analysis, patients who received high-dose conditioning vs intermediate-dose conditioning had a survival advantage; actuarial median survival was 31.5 months in the intermediate-dose group but has not been reached in the high-dose group (Figure 3) . However, in February 2004, only 21 of 120 in the high-dose group and 22 of 54 in the intermediate-dose group had died, reflecting the tentative nature of these conclusions. A landmark analysis was performed on those patients surviving beyond day þ 100. Conditioning intensity remained a significant predictor of survival (P ¼ 0.002).
Response rates were compared among the 150 patients who survived until day 100, excluding those 21 who died early who would be considered inevaluable for a hematologic response. Overall, of the 120 high-dose patients, 109 survived to the point of evaluation and 89 (81%) achieved a response. Among the 51 intermediate-dose patients, 41 survived until day 100 and 26 achieved a hematologic response (63%). The difference between the groups was statistically significant (P ¼ 0.02).
Discussion
Melphalan and prednisone have been used to treat AL since 1972, 16 but only a minority of patients responded, and the median survival is no longer than 18 months. The introduction of autologous stem cell transplantation was logical because it produces a clear survival advantage in patients with multiple myeloma. 17 Stem cell transplantation for multiple myeloma appears to benefit patients who come to transplant with a lower tumor burden. This advantage makes its use appealing in AL patients whose median number of plasma cells in bone marrow is 5%. The previously reported response rates for transplantation to treat this selected group of AL patients are consistently higher than 60%. 18, 19 Stem cell transplantation has substantial complications, however. 20 In our data set, the patients with an elevated serum creatinine value and a higher number of involved organs had higher treatment-related mortality. 21 In addition, patients with multiorgan involvement or overt congestive heart failure may be excluded from undergoing stem cell transplantation 22 and thus would not be included in this data set. Most investigators believe that renal insufficiency, 21 advanced age, multiorgan dysfunction, and overt heart failure result in excessive mortality after chemotherapy, and these are exclusion criteria in most protocols. In one multicenter survey, the mortality from transplant-related complications was 43%. 22 Another survey reported 30% treatment-related mortality. 20 Saba et al 20 demonstrated high treatment-related mortality in patients with cardiac AL.
Despite the high mortality associated with transplantation, the observed response rate exceeds that seen with conventional oral chemotherapy alone. 23 Therefore, attempts have been made to render more patients eligible to undergo stem cell transplantation by reducing the intensity of conditioning. A risk-adapted approach has been described that uses lower doses of chemotherapy in patients who have multiorgan involvement, are older, and have renal insufficiency. 5 In transplantation for multiple myeloma, the dose of melphalan and its impact on response was demonstrated 20 years ago. 24, 25 Our data suggest that dose de-escalation reduces the response rate. The two groups in this study were unbalanced. Patients who received lower conditioning had higher creatinine and serum b 2 -microglobulin levels 26 and had increased ventricular septal thickness and reduced ejection fraction; population differences may account for the lower response rate. However, in the myeloma literature, it has not been established that age or creatinine values make a patient less likely to respond to high-dose chemotherapy. [27] [28] [29] [30] [31] Moreover, there is no a priori reason to believe that greater degrees of cardiac involvement should affect the ability of chemotherapy to eradicate the plasma cell clone and the immunoglobulin light chains they produce. There was not a lower response rate in patients with two or more than two organs involved. If patients receiving higher doses were inherently destined to do well, one would expect nonresponders in the high-dose group to do better than intermediate-dose nonresponders, but this was not the case. We believe that intermediate-dose melphalan reduces the mortality of stem cell transplantation in the high-risk group we defined. Mortality of 20% at post transplant day 100 in the intermediate-dose group is lower than would be expected. The group at Boston University has also reported an effect of melphalan dose on the probability of a complete response for 181 patients with AL. Patients receiving 200 mg of melphalan/m 2 had higher response rates than those treated with 100-140 mg/m 2 . They also recognized that the propensity score they used for determining the dose of melphalan would confound an estimate of the effect of dose on survival. 32 The difference in response rates between the high-and intermediate-dose conditioning groups does not prove that stem cell transplantation is superior management of patients with AL. No phase 3 study has been performed to demonstrate a survival advantage for patients who undergo stem cell transplantation compared with those who are treated with less intensive forms of therapy. Lachmann et al 33 have demonstrated that eligibility for stem cell transplantation is an important predictor of improved survival. We continue to apply transplantation to selected AL patients and continue to treat poor-prognosis patients with lowerintensity chemotherapy to minimize treatment-related mortality. Patients failing to respond to transplant have a poor outcome and become candidates for salvage nonmyeloablative therapies. We do not have sufficient followup yet to assess the actuarial median survival of these patients, the long-term risk of myelodysplastic syndrome, or the risk of relapse. We do believe that autologous stem cell transplantation is an effective therapy for many AL patients, including those conditioned with intermediate doses. This group achieves a response rate of 53%.
The current preliminary observation may have resulted from either patient selection or differences in melphalan dosage. A prospective study is required to evaluate the role of dose manipulation in low-risk patients and to clarify the implications of variable response to overall survival and improvement in quality of life.
